Cameron D Thomas

Postdoctoral Associate

Department: Pharmacotherapy & Translational Research

Business Phone: (352) 273-6446

Business Email: camerondthomas@cop.ufl.edu

2021

A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.

Genetics in medicine : official journal of the American College of Medical Genetics. [DOI] 10.1038/s41436-020-01050-4. [PMID] 33420349.

2020

Pharmacogenetic factors affecting β-blocker metabolism and response.

Expert opinion on drug metabolism & toxicology. 16(10):953-964 [DOI] 10.1080/17425255.2020.1803279. [PMID] 32726152.

2020

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Clinical pharmacology and therapeutics. [DOI] 10.1002/cpt.2039. [PMID] 32897581.

2020

Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.

CPT: pharmacometrics & systems pharmacology. 9(12):678-685 [DOI] 10.1002/psp4.12563. [PMID] 33067866.

2020

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.

Clinical pharmacology and therapeutics. [DOI] 10.1002/cpt.2015. [PMID] 32770672.

2019

Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease.

Journal of clinical pharmacy and therapeutics. 44(1):109-114 [DOI] 10.1111/jcpt.12767. [PMID] 30311242.

Phones:

Emails: